Chinese HER2 Bispecific Antibody + PD-1 Combination Approved in the U.S. for Gastroesophageal Adenocarcinoma, Advancing to the Forefront of Global Oncology

The U.S. FDA approved zanidatamab with tislelizumab and chemotherapy as a first-line treatment option for adults with HER2-positive unresectable locally advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma.

Top Stories

Latest Coverage

Breaking Through for an Asian Cancer: China’s Innovation Rewrites the Future of Nasopharyngeal Cancer Treatment
What happens when a patient with nasopharyngeal cancer sees the disease progress again after first- and second-line t...
Sevabertinib for HER2-Mutant NSCLC in China: A New Targeted Treatment Option
From EGFR and ALK to ROS1, RET, MET, and HER2, advances in genetic testing and targeted therapies are enabling more p...
Current Status of Immunotherapy for Bladder Cancer: From BCG to Precision Combination Therapy
Bladder cancer is one of the most common malignancies of the urinary system. A substantial proportion of patients are...
Are Women More Prone to Thyroid Cancer? Causes and Prevention Explained
In recent years, the incidence of thyroid cancer has been rising globally. One notable feature is that women are affe...
From Health Checkups to Cancer Treatment: China’s Medical Travel Market Is Rapidly Expanding
From Health Checkups to Cancer Treatment: China’s Medical Travel Market Is Rapidly Expanding
Where Pancreatic Cancer Develops Matters: Understanding Pancreatic Head Cancer vs. Body and Tail Cancer
Pancreatic cancer is a malignant tumor that develops in the pancreas. While many people know that pancreatic cancer c...

In-Depth Analysis


This site uses Just the Docs, a documentation theme for Jekyll.